Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors †
Pınar Kubilay Tolunay, Bediz Kurt İnci, Şura Usta, Ali Topkaç, Berkan Karabuğa, Ergin Aydemir, İrem Öner, Büşra Akay Hacan, Öztürk Ateş, Cengiz Karaçin, Ülkü Yalçıntaş Arslan · 2024
Read Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors † by Pınar Kubilay Tolunay, Bediz Kurt İnci, Şura Usta, Ali Topkaç, Berkan Karabuğa, Ergin Aydemir, İrem Öner, Büşra Akay Hacan, Öztürk Ateş, Cengiz Karaçin, Ülkü Yalçıntaş Arslan (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11674770.txt.
Description
Pınar Kubilay Tolunay and co-authors report a 2024 study of dose cuts in breast cancer drugs called CDK4/6 inhibitors. The team tracked 392 patients with metastatic breast cancer treated in Turkey with ribociclib or palbociclib between 2019 and 2023.
Side effects often force doctors to lower the dose, and the study asked whether the timing of that cut changes survival. Patients whose dose fell in the first three months had the shortest time before the cancer grew again, at about 14 months. Those cut later did best, at about 33 months, while patients with no cut sat near 21 months. Low white cell counts were the most common reason for cutting the dose.
Catalog record
| CREATOR | Pınar Kubilay Tolunay, Bediz Kurt İnci, Şura Usta, Ali Topkaç, Berkan Karabuğa, Ergin Aydemir, İrem Öner, Büşra Akay Hacan, Öztürk Ateş, Cengiz Karaçin, Ülkü Yalçıntaş Arslan |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |